Please login to the form below

Not currently logged in
Email:
Password:

Cinqaero

This page shows the latest Cinqaero news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

Teva’s Cinqaero is also on the NICE-approved list of treatments for this severe and potentially life-threatening form of asthma, having gained recommendation last year.

Latest news

  • AZ’s Fasenra hit by COPD trial failure AZ’s Fasenra hit by COPD trial failure

    A third IL-5 inhibitor – Teva’s Cinqair/Cinqaero (reslizumab) – has been available since 2016 but in an intravenous formulation only, and the company’s attempts to develop a subcutaneous version

  • AZ gets EMA green light for severe asthma drug Fasenra AZ gets EMA green light for severe asthma drug Fasenra

    AZ gets EMA green light for severe asthma drug Fasenra. The biologic respiratory treatment will go up against GSK’s Nucala and Teva’s Cinqaero. ... Fasenra (benralizumab) is the third IL-5-targetting drug approved for market after GlaxoSmithKline’s

  • GSK gets another approval for Nucala in US GSK gets another approval for Nucala in US

    which include AstraZeneca with recently approved Fasenra (benralizumab) and Teva’s Cinqair/Cinqaero (reslizumab).

  • AZ prices severe asthma drug Fasenra below competition AZ prices severe asthma drug Fasenra below competition

    battle to its competitors by pricing the drug at a discount to GSK’s Nucala (mepolizumab) and Teva’s Cinqair/Cinqaero (reslizumab) - also IL-5 inhibitors. ... Like Nucala it is administered by subcutaneous injections while Cinqaero requires an

  • AZ severe asthma drug benralizumab backed by CHMP AZ severe asthma drug benralizumab backed by CHMP

    AZ is vying to make the drug the third IL-5 inhibitor to reach the market for severe asthma after GlaxoSmithKline’s Nucala (mepolizumab) and Teva's Cinqaero (reslizumab), and says

More from news
Approximately 6 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics